Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 362,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "5adeb772-31ff-4193-8e4a-f28d4de030a4",
"title": "Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)",
"description": "Chief Financial Officer Michael Brophy sold 2,359 shares of Natera Inc (NTRA) on July 26, 2024, as reported in a recent SEC Filing. Following this transaction,",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NTRA",
"snippet": "Chief Financial Officer Michael Brophy sold 2,359 shares of Natera Inc (NTRA, Financial) on July 26, 2024, as reported in a recent SEC Filing. Following this tr...",
"url": "https://www.gurufocus.com/news/2483713/insider-sale-cfo-michael-brophy-sells-shares-of-natera-inc-ntra",
"image_url": "https://static.gurufocus.com/logos/0C0000AXCK.png?14",
"language": "en",
"published_at": "2024-07-27T05:00:41.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "NTRA",
"name": "Natera, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.184555,
"sentiment_score": 0.385275,
"highlights": [
{
"highlight": "Chief Financial Officer Michael Brophy sold 2,359 shares of <em>Natera</em> <em>Inc</em> (NTRA, Financial) on July 26, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 75,059 shares of the company.\n\n<em>Natera</em> <em>Inc</em> specializes in genetic testing and diagnostics with a focus on prenatal, oncological, and organ health tests.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "This recent sale is part of a broader trend seen within <em>Natera</em> <em>Inc</em>, where there have been 93 insider sells and no insider buys over the last year.\n\nShares of <em>Natera</em> <em>Inc</em> were priced at $104.39 on the day of the transaction. The company's market cap is approximately $12.60 billion.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "According to the GF Value, the intrinsic value estimate for <em>Natera</em> <em>Inc</em> is $71.79 per share, making the stock significantly overvalued with a price-to-GF-Value ratio of 1.45.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Sale: CFO Michael Brophy Sells Shares of <em>Natera</em> <em>Inc</em> (NTRA)",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "b31d56c0-f37b-43ab-9eb4-f17a57d28efb",
"title": "Natera CFO sells over $246k in company stock By Investing.com",
"description": "Natera CFO sells over $246k in company stock",
"keywords": "",
"snippet": "Michael Burkes, the Chief Financial Officer of Natera, Inc. (NASDAQ: ), a leader in personalized genetic testing and diagnostics, has recently sold shares of th...",
"url": "https://www.investing.com/news/company-news/natera-cfo-sells-over-246k-in-company-stock-93CH-3540231",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-07-27T01:41:56.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "NTRA",
"name": "Natera, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 59.71629,
"sentiment_score": 0.478391,
"highlights": [
{
"highlight": "Michael Burkes, the Chief Financial Officer of <em>Natera</em>, <em>Inc</em>. (NASDAQ: ), a leader in personalized genetic testing and diagnostics, has recently sold shares of the company stock, according to a new SEC filing. Over a span of three days, Burkes sold a total of 2,359 shares, resulting in proceeds of over $246,000.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Following these transactions, the SEC filing indicated that Burkes still owned 75,059 shares of <em>Natera</em> stock.\n\nThese transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission, which is used to report a change in company insiders' ownership positions.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "In other recent news, <em>Natera</em> <em>Inc</em> . has reported significant progress in the genetic testing industry. The company has seen a robust 18% sequential revenue increase and a 52% rise year-over-year in Q1 2024, leading to an upward revision of their revenue guidance for the year.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "Piper Sandler reaffirmed its positive stance on <em>Natera</em>, maintaining an Overweight rating, while Wolfe Research and Jefferies both maintained positive ratings for the company.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Natera</em> has also made strides in debt management, announcing the full redemption of its outstanding 2.25% Convertible Senior Notes due 2027, totaling a principal amount of $287.5 million.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\nAs investors digest the news of insider sales by <em>Natera</em>, <em>Inc</em>.'s CFO, Michael Burkes, it's crucial to consider the company's financial health and market performance to understand the broader context.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "While analysts do not anticipate <em>Natera</em> will be profitable this year, the company has had a high return over the last year, with a 126.54% one-year price total return as of the provided data date. This could suggest investor optimism about the company's long-term growth potential.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Tips for <em>Natera</em> also reveal that the company is trading at a high Price / Book multiple of 15.88, which may indicate the stock is valued richly compared to its book value.",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>Natera</em> does not pay a dividend to shareholders, which is a common characteristic of growth-oriented companies that prefer to reinvest earnings into the business rather than distribute them as dividends.",
"sentiment": 0.0302,
"highlighted_in": "main_text"
},
{
"highlight": "There are 9 more InvestingPro Tips available for <em>Natera</em>, which can be accessed through the InvestingPro platform. These insights could be particularly valuable for current and potential shareholders evaluating the company's prospects in light of the CFO's recent stock sales.",
"sentiment": 0.6771,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Natera</em> CFO sells over $246k in company stock By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "d871c949-d40f-4e56-9310-fb20586102c5",
"title": "Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals Inc (CRNX)",
"description": "Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (CRNX) on July 25, 2024, as reported in a recent SEC Filing. Following",
"keywords": "GuruFocus, Article, News, GuruFocus Research, CRNX",
"snippet": "Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (CRNX, Financial) on July 25, 2024, as reported in a recent SEC Filing....",
"url": "https://www.gurufocus.com/news/2483631/insider-sale-chief-scientific-officer-stephen-betz-sells-shares-of-crinetics-pharmaceuticals-inc-crnx",
"image_url": "https://static.gurufocus.com/logos/0C0000BH66.png?14",
"language": "en",
"published_at": "2024-07-26T23:00:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CRNX",
"name": "Crinetics Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 129.66629,
"sentiment_score": 0.4614,
"highlights": [
{
"highlight": "Chief Scientific Officer Stephen Betz sold 3,000 shares of <em>Crinetics</em> <em>Pharmaceuticals</em> <em>Inc</em> (CRNX, Financial) on July 25, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 75,611 shares of the company.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crinetics</em> <em>Pharmaceuticals</em> <em>Inc</em> is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.\n\nOver the past year, Stephen Betz has sold a total of 33,000 shares of <em>Crinetics</em> <em>Pharmaceuticals</em> <em>Inc</em> and has not made any purchases of the stock.",
"sentiment": 0.7269,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of <em>Crinetics</em> <em>Pharmaceuticals</em> <em>Inc</em> were trading at $53.43 on the day of the transaction. The company currently holds a market cap of approximately $4.29 billion.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of <em>Crinetics</em> <em>Pharmaceuticals</em> <em>Inc</em> (CRNX)",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "924f43a0-226b-43df-a15c-077e91413cf4",
"title": "Why Is UnitedHealth Group Incorporated (UNH) the Best Health Insurance Stock Right Now?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where UnitedHealth Group Incorporated...",
"url": "https://www.insidermonkey.com/blog/why-is-unitedhealth-group-incorporated-unh-the-best-health-insurance-stock-right-now-1326751/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/19161417/UNH-insidermonkey-1695154454514.jpg",
"language": "en",
"published_at": "2024-07-27T02:55:20.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "UNHH34.SA",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 143.19057,
"sentiment_score": 0.247038,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH)\n\nNumber of Hedge Fund Holders: 104\n\n<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH), headquartered in Minnetonka, Minnesota, is a leading American multinational corporation specializing in managed healthcare and insurance services.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Financial institutions are keeping a close eye on <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH)’s performance, with analysts predicting continued growth and profitability. Notably, Piper Sandler recently maintained an Overweight rating on UNH shares, highlighting a positive outlook for the company’s expansion in the Medicare Advantage sector.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "In Q1 2024, Insider Monkey’s research revealed that 104 hedge funds held stakes in <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH). The largest stakeholder was Ken Fisher’s Fisher Asset Management, with a $1.4 billion investment.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Despite its strong performance, <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH) has faced challenges, including a cyberattack on its technology unit that exploited a vulnerability in Citrix software.",
"sentiment": -0.6456,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH) recently reported issues with Medicaid enrollment, which has caused disruptions in reimbursement rates and led to an overall decline in health insurer stocks.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Baron Funds stated the following regarding <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH) in its first quarter 2024 investor letter:\n\n“<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (NYSE:UNH) is a leading health insurance company that operates across four segments: United Healthcare, Optum Health, OptumInsight, and OptumRX.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Why Is <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (UNH) the Best Health Insurance Stock Right Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "UNH",
"name": "UnitedHealth Group Incorporated",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 161.34879,
"sentiment_score": 0.247038,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>)\n\nNumber of Hedge Fund Holders: 104\n\n<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>), headquartered in Minnetonka, Minnesota, is a leading American multinational corporation specializing in managed healthcare and insurance services.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Financial institutions are keeping a close eye on <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>)’s performance, with analysts predicting continued growth and profitability. Notably, Piper Sandler recently maintained an Overweight rating on UNH shares, highlighting a positive outlook for the company’s expansion in the Medicare Advantage sector.",
"sentiment": 0.8402,
"highlighted_in": "main_text"
},
{
"highlight": "In Q1 2024, Insider Monkey’s research revealed that 104 hedge funds held stakes in <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>). The largest stakeholder was Ken Fisher’s Fisher Asset Management, with a $1.4 billion investment.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Despite its strong performance, <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>) has faced challenges, including a cyberattack on its technology unit that exploited a vulnerability in Citrix software.",
"sentiment": -0.6456,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>) recently reported issues with Medicaid enrollment, which has caused disruptions in reimbursement rates and led to an overall decline in health insurer stocks.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Baron Funds stated the following regarding <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>) in its first quarter 2024 investor letter:\n\n“<em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (<em>NYSE:UNH</em>) is a leading health insurance company that operates across four segments: United Healthcare, Optum Health, OptumInsight, and OptumRX.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Why Is <em>UnitedHealth</em> <em>Group</em> <em>Incorporated</em> (UNH) the Best Health Insurance Stock Right Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "71b65cae-9c0c-4e37-8e31-390d60ed3c4c",
"title": "Elevance Health, Inc. (ELV): Did This Health Insurance Stock Get a Buy Rating from Analysts?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where Elevance Health, Inc.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where Elevance Health, Inc. (NYSE:ELV...",
"url": "https://www.insidermonkey.com/blog/elevance-health-inc-elv-did-this-health-insurance-stock-get-a-buy-rating-from-analysts-1326745/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/20061241/ELV-insidermonkey-1695204759756.jpg",
"language": "en",
"published_at": "2024-07-27T02:40:22.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK.MX",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Financial Services",
"match_score": 11.531286,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ANTM",
"name": "Anthem, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.743672,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "(NYSE:ELV)\n\nNumber of Hedge Fund Holders: 79\n\nFormerly known as <em>Anthem</em>, <em>Inc</em>., Elevance Health, Inc. (NYSE:ELV) is a health benefits company operating in the United States through its subsidiaries. The company manages Blue Cross and Blue Shield plans in 14 states and holds licenses to sell health insurance nationwide.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 11.531115,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ANTM.MX",
"name": "Anthem, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.743676,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "(NYSE:ELV)\n\nNumber of Hedge Fund Holders: 79\n\nFormerly known as <em>Anthem</em>, <em>Inc</em>., Elevance Health, Inc. (NYSE:ELV) is a health benefits company operating in the United States through its subsidiaries. The company manages Blue Cross and Blue Shield plans in 14 states and holds licenses to sell health insurance nationwide.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0HG8.L",
"name": "Anthem, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 12.743569,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "(NYSE:ELV)\n\nNumber of Hedge Fund Holders: 79\n\nFormerly known as <em>Anthem</em>, <em>Inc</em>., Elevance Health, Inc. (NYSE:ELV) is a health benefits company operating in the United States through its subsidiaries. The company manages Blue Cross and Blue Shield plans in 14 states and holds licenses to sell health insurance nationwide.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 11.530846,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "A1NT34.SA",
"name": "Anthem, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 12.744934,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "(NYSE:ELV)\n\nNumber of Hedge Fund Holders: 79\n\nFormerly known as <em>Anthem</em>, <em>Inc</em>., Elevance Health, Inc. (NYSE:ELV) is a health benefits company operating in the United States through its subsidiaries. The company manages Blue Cross and Blue Shield plans in 14 states and holds licenses to sell health insurance nationwide.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "253d7c86-a6fd-4728-986c-b38aa8e5873c",
"title": "Humana Inc. (HUM): Street Analysts are Bullish on This Health Insurance Stock Now",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where Humana Inc.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where Humana Inc. (NYSE:HUM) stands a...",
"url": "https://www.insidermonkey.com/blog/humana-inc-hum-street-analysts-are-bullish-on-this-health-insurance-stock-now-1326742/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/20133031/HUM-insidermonkey-1695231029118.jpg",
"language": "en",
"published_at": "2024-07-27T02:35:15.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK.MX",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797828,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HUM.MX",
"name": "Humana Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.702778,
"sentiment_score": 0.171729,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Humana</em> <em>Inc</em>. (NYSE:HUM) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (NYSE:HUM)\n\nNumber of Hedge Fund Holders: 74\n\n<em>Humana</em> <em>Inc</em>. (NYSE:HUM) is dedicated to enhancing health and well-being by providing healthcare benefits to its medical and specialty members.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald recently adjusted its price target for <em>Humana</em> <em>Inc</em>. (NYSE:HUM) to $360 from the previous target of $391 set in April, while maintaining a Neutral rating on the stock. This revision follows Humana’s first-quarter earnings report, which surpassed expected financial metrics.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (NYSE:HUM)’s medical loss ratio (MLR), a critical measure of the amount spent on medical claims relative to the insurance premiums collected, was 89.3%, slightly higher than the consensus of 88.9%.",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald analysts pointed out that although <em>Humana</em> <em>Inc</em>. (NYSE:HUM) has maintained its full-year MLR at 90% and its EPS forecast at approximately $16, there remains some uncertainty about the new guidance for 2025.\n\nAccording to Insider Monkey, 30 out of the 919 hedge funds tracked reported owning stock in <em>Humana</em> <em>Inc</em>.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Diamond Hill Large Cap Strategy stated the following regarding <em>Humana</em> <em>Inc</em>. (NYSE:HUM) in its first quarter 2024 investor letter:\n\n“Among our bottom Q1 contributors were real estate investment trusts (REITs) Extra Space Storage and SBA Communications, as well as <em>Humana</em> <em>Inc</em>. (NYSE:HUM).",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (HUM): Street Analysts are Bullish on This Health Insurance Stock Now",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797673,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HUM",
"name": "Humana Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.567753,
"sentiment_score": 0.237063,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>)\n\nNumber of Hedge Fund Holders: 74\n\n<em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>) is dedicated to enhancing health and well-being by providing healthcare benefits to its medical and specialty members.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald recently adjusted its price target for <em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>) to $360 from the previous target of $391 set in April, while maintaining a Neutral rating on the stock. This revision follows Humana’s first-quarter earnings report, which surpassed expected financial metrics.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>)’s medical loss ratio (MLR), a critical measure of the amount spent on medical claims relative to the insurance premiums collected, was 89.3%, slightly higher than the consensus of 88.9%.",
"sentiment": -0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald analysts pointed out that although <em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>) has maintained its full-year MLR at 90% and its EPS forecast at approximately $16, there remains some uncertainty about the new guidance for 2025.\n\nAccording to Insider Monkey, 30 out of the 919 hedge funds tracked reported owning stock in <em>Humana</em> <em>Inc</em>.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NYSE:HUM</em>) as of Q1 2024. Among the top hedge fund investors in the company, Citadel Asset Management held a notable stake valued at over $372.4 million.\n\nDiamond Hill Large Cap Strategy stated the following regarding <em>Humana</em> <em>Inc</em>.",
"sentiment": 0.8225,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NYSE:HUM</em>) in its first quarter 2024 investor letter:\n\n“Among our bottom Q1 contributors were real estate investment trusts (REITs) Extra Space Storage and SBA Communications, as well as <em>Humana</em> <em>Inc</em>. (<em>NYSE:HUM</em>).",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (HUM): Street Analysts are Bullish on This Health Insurance Stock Now",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0J6Z.L",
"name": "Humana Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 69.86478,
"sentiment_score": 0.36351,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Humana</em> <em>Inc</em>. (NYSE:HUM) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (NYSE:HUM)\n\nNumber of Hedge Fund Holders: 74\n\n<em>Humana</em> <em>Inc</em>. (NYSE:HUM) is dedicated to enhancing health and well-being by providing healthcare benefits to its medical and specialty members.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald recently adjusted its price target for <em>Humana</em> <em>Inc</em>. (NYSE:HUM) to $360 from the previous target of $391 set in April, while maintaining a Neutral rating on the stock. This revision follows Humana’s first-quarter earnings report, which surpassed expected financial metrics.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> reported an EPS of $7.23 for Q1 2024, exceeding the FactSet consensus of $6.12. The company’s revenue reached $29.6 billion, surpassing the expected $28.5 billion. <em>Humana</em> <em>Inc</em>.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "Cantor Fitzgerald analysts pointed out that although <em>Humana</em> <em>Inc</em>. (NYSE:HUM) has maintained its full-year MLR at 90% and its EPS forecast at approximately $16, there remains some uncertainty about the new guidance for 2025.\n\nAccording to Insider Monkey, 30 out of the 919 hedge funds tracked reported owning stock in <em>Humana</em> <em>Inc</em>.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Diamond Hill Large Cap Strategy stated the following regarding <em>Humana</em> <em>Inc</em>. (NYSE:HUM) in its first quarter 2024 investor letter:\n\n“Among our bottom Q1 contributors were real estate investment trusts (REITs) Extra Space Storage and SBA Communications, as well as <em>Humana</em> <em>Inc</em>. (NYSE:HUM).",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "Shares of health insurance company <em>Humana</em> were meaningfully pressured in late 2023 against a backdrop of accelerating medical costs among its Medicare population, weighing on health plan profitability.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Further, since Medicare Advantage plan pricing is set in June of each year for the following year, <em>Humana</em> is unable to offset increased medical costs with higher pricing — which in turn pressured shares in Q1.",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Nevertheless, we anticipate <em>Humana</em> will be able to improve margins over the next several years and maintain our conviction in our position.”\n\nOverall HUM ranks 4th on our list of the best health insurance stocks to buy. You can visit 10 Best Health Insurance Stocks to Buy to see the other health insurance stocks that are on hedge funds’ radar.",
"sentiment": 0.9062,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Humana</em> <em>Inc</em>. (HUM): Street Analysts are Bullish on This Health Insurance Stock Now",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 10.797423,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "b3167d85-401c-4091-94b6-ceee2871eae6",
"title": "Why Are Hedge Funds Bullish on The Cigna Group (CI) Right Now?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where The Cigna Group (NYSE:CI) stand...",
"url": "https://www.insidermonkey.com/blog/why-are-hedge-funds-bullish-on-the-cigna-group-ci-right-now-1326736/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/20090459/CI-insidermonkey-1695215097592.jpg",
"language": "en",
"published_at": "2024-07-27T02:25:46.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK.MX",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797828,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797673,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CI",
"name": "Cigna Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 52.06619,
"sentiment_score": 0.622036,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where The <em>Cigna</em> Group (<em>NYSE:CI</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Cigna</em> Group (<em>NYSE:CI</em>)\n\nNumber of Hedge Fund Holders: 61\n\nThe <em>Cigna</em> Group (<em>NYSE:CI</em>) and its subsidiaries specialize in offering insurance and related products and services in the United States. The company also provides pharmacy benefits, home delivery pharmacy, and specialty pharmacy distribution services.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Cigna</em> Group (<em>NYSE:CI</em>) reported a notable first-quarter, with sales of $57.26 billion, a 23% year-over-year increase, surpassing the consensus estimate of $55.47 billion. This growth was primarily driven by substantial gains in Evernorth Health Services, reflecting multiple large client acquisitions.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Adjusted income from operations rose 16% to $1.88 billion, with strong contributions from both <em>Cigna</em> Healthcare and Evernorth Health Services. <em>Cigna</em> Healthcare sales increased 4% year-over-year to $13.3 billion, reflecting premium rate adjustments.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Following The <em>Cigna</em> Group (<em>NYSE:CI</em>)’s strong first-quarter financial results, RBC Capital Markets slightly raised its price target for CI shares to $384 from $383, while maintaining an Outperform rating.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "RBC’s assessment was also influenced by Cigna’s recent investor day, during which the company raised its long-term growth targets to a range of 10-14%, a projection RBC believes is justified based on The <em>Cigna</em> Group (<em>NYSE:CI</em>)’s current performance and trajectory.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "Hedge fund sentiment towards The <em>Cigna</em> Group (<em>NYSE:CI</em>) appears positive, with 61 funds holding significant stakes in the company as of Q1 2024. The largest position is held by Glenview Capital, which owns 1.47 million shares valued at $534.3 million.",
"sentiment": 0.8591,
"highlighted_in": "main_text"
},
{
"highlight": "Here is what Davis New York Venture Fund has to say about The <em>Cigna</em> Group (<em>NYSE:CI</em>) in its Q3 2023 investor letter:\n\n“In the attractive healthcare sector, we look beyond the obvious to identify businesses that simultaneously have exposure to this growth industry and also trade at low prices.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "We’re especially drawn to companies like <em>Cigna</em> Group, whose products or services play a part in helping to mitigate healthcare’s constantly rising costs. The healthcare industry has been a growing part of the U.S. economy for decades.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "As a result, we have positions in <em>Cigna</em> Group, a well-regarded provider of managed care.\n\nOverall CI ranks 6th on our list of the best health insurance stocks to buy. You can visit 10 Best Health Insurance Stocks to Buy to see the other health insurance stocks that are on hedge funds’ radar.",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "Why Are Hedge Funds Bullish on The <em>Cigna</em> Group (CI) Right Now?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 10.797423,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "ad544621-8f51-489b-82bc-43d4cb901bb5",
"title": "Centene Corporation (CNC): Do Hedge Funds Recommend This Health Insurance Stock Right Now?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where Centene Corporation (NYSE:CNC) ...",
"url": "https://www.insidermonkey.com/blog/centene-corporation-cnc-do-hedge-funds-recommend-this-health-insurance-stock-right-now-1326731/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/22051242/CNC-insidermonkey-1695373960033.jpg",
"language": "en",
"published_at": "2024-07-27T02:19:31.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK.MX",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797828,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CNC.MX",
"name": "Centene Corporation",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 86.08524,
"sentiment_score": 0.62656,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Centene</em> <em>Corporation</em> (NYSE:CNC) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC)\n\nNumber of Hedge Fund Holders: 56\n\n<em>Centene</em> <em>Corporation</em> (NYSE:CNC), based in St. Louis, Missouri, is a publicly traded managed care firm that acts as an intermediary for both government-sponsored and privately insured healthcare programs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) reported first-quarter profits of $1.1 billion, driven by an increase in membership and premium revenue, thanks to a significant rise in Obamacare enrollment.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) also raised its 2024 diluted earnings per share guidance floor to more than $5.94 and its adjusted diluted EPS guidance floor to more than $6.80.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Among the largest hedge fund shareholders of <em>Centene</em> <em>Corporation</em> (NYSE:CNC) is Harris Associates, holding shares valued at $1.33 billion.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Oakmark Global Fund stated the following regarding <em>Centene</em> <em>Corporation</em> (NYSE:CNC) in its first quarter 2024 investor letter:\n\n“<em>Centene</em> <em>Corporation</em> (NYSE:CNC) is a large health insurer specializing in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "In Medicaid, states are steadily outsourcing their programs to managed care companies like <em>Centene</em> to help reduce costs and improve care quality. Managed Medicaid penetration has increased meaningfully over the past two decades, and we expect further gains over time.",
"sentiment": 0.9517,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> holds the top market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, in Centene’s Medicare Advantage business, past missteps will result in losses next year, but we believe <em>Centene</em> can turn its Medicare Advantage segment around and generate positive earnings in the next few years.",
"sentiment": 0.8705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> currently trades for about 9x our estimate of normal earnings power, which we believe is a compelling value for a business that generates healthy returns on capital and is capable of growing EPS at a low double-digit rate.”\n\nOverall CNC ranks 7th on our list of the best health insurance stocks to buy.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (CNC): Do Hedge Funds Recommend This Health Insurance Stock Right Now?",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
},
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797673,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CNC",
"name": "Centene Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 105.72368,
"sentiment_score": 0.62656,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>)\n\nNumber of Hedge Fund Holders: 56\n\n<em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>), based in St. Louis, Missouri, is a publicly traded managed care firm that acts as an intermediary for both government-sponsored and privately insured healthcare programs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) reported first-quarter profits of $1.1 billion, driven by an increase in membership and premium revenue, thanks to a significant rise in Obamacare enrollment.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) also raised its 2024 diluted earnings per share guidance floor to more than $5.94 and its adjusted diluted EPS guidance floor to more than $6.80.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Among the largest hedge fund shareholders of <em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) is Harris Associates, holding shares valued at $1.33 billion.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Oakmark Global Fund stated the following regarding <em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) in its first quarter 2024 investor letter:\n\n“<em>Centene</em> <em>Corporation</em> (<em>NYSE:CNC</em>) is a large health insurer specializing in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "In Medicaid, states are steadily outsourcing their programs to managed care companies like <em>Centene</em> to help reduce costs and improve care quality. Managed Medicaid penetration has increased meaningfully over the past two decades, and we expect further gains over time.",
"sentiment": 0.9517,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> holds the top market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, in Centene’s Medicare Advantage business, past missteps will result in losses next year, but we believe <em>Centene</em> can turn its Medicare Advantage segment around and generate positive earnings in the next few years.",
"sentiment": 0.8705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> currently trades for about 9x our estimate of normal earnings power, which we believe is a compelling value for a business that generates healthy returns on capital and is capable of growing EPS at a low double-digit rate.”\n\nOverall CNC ranks 7th on our list of the best health insurance stocks to buy.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (CNC): Do Hedge Funds Recommend This Health Insurance Stock Right Now?",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HVB.L",
"name": "Centene Corporation",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 86.06985,
"sentiment_score": 0.62656,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Centene</em> <em>Corporation</em> (NYSE:CNC) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC)\n\nNumber of Hedge Fund Holders: 56\n\n<em>Centene</em> <em>Corporation</em> (NYSE:CNC), based in St. Louis, Missouri, is a publicly traded managed care firm that acts as an intermediary for both government-sponsored and privately insured healthcare programs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) reported first-quarter profits of $1.1 billion, driven by an increase in membership and premium revenue, thanks to a significant rise in Obamacare enrollment.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) also raised its 2024 diluted earnings per share guidance floor to more than $5.94 and its adjusted diluted EPS guidance floor to more than $6.80.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Among the largest hedge fund shareholders of <em>Centene</em> <em>Corporation</em> (NYSE:CNC) is Harris Associates, holding shares valued at $1.33 billion.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Oakmark Global Fund stated the following regarding <em>Centene</em> <em>Corporation</em> (NYSE:CNC) in its first quarter 2024 investor letter:\n\n“<em>Centene</em> <em>Corporation</em> (NYSE:CNC) is a large health insurer specializing in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "In Medicaid, states are steadily outsourcing their programs to managed care companies like <em>Centene</em> to help reduce costs and improve care quality. Managed Medicaid penetration has increased meaningfully over the past two decades, and we expect further gains over time.",
"sentiment": 0.9517,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> holds the top market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, in Centene’s Medicare Advantage business, past missteps will result in losses next year, but we believe <em>Centene</em> can turn its Medicare Advantage segment around and generate positive earnings in the next few years.",
"sentiment": 0.8705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> currently trades for about 9x our estimate of normal earnings power, which we believe is a compelling value for a business that generates healthy returns on capital and is capable of growing EPS at a low double-digit rate.”\n\nOverall CNC ranks 7th on our list of the best health insurance stocks to buy.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (CNC): Do Hedge Funds Recommend This Health Insurance Stock Right Now?",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 10.797423,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "C1NC34.SA",
"name": "Centene Corporation",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 86.12451,
"sentiment_score": 0.62656,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>Centene</em> <em>Corporation</em> (NYSE:CNC) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC)\n\nNumber of Hedge Fund Holders: 56\n\n<em>Centene</em> <em>Corporation</em> (NYSE:CNC), based in St. Louis, Missouri, is a publicly traded managed care firm that acts as an intermediary for both government-sponsored and privately insured healthcare programs.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) reported first-quarter profits of $1.1 billion, driven by an increase in membership and premium revenue, thanks to a significant rise in Obamacare enrollment.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (NYSE:CNC) also raised its 2024 diluted earnings per share guidance floor to more than $5.94 and its adjusted diluted EPS guidance floor to more than $6.80.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Among the largest hedge fund shareholders of <em>Centene</em> <em>Corporation</em> (NYSE:CNC) is Harris Associates, holding shares valued at $1.33 billion.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Oakmark Global Fund stated the following regarding <em>Centene</em> <em>Corporation</em> (NYSE:CNC) in its first quarter 2024 investor letter:\n\n“<em>Centene</em> <em>Corporation</em> (NYSE:CNC) is a large health insurer specializing in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage.",
"sentiment": 0.25,
"highlighted_in": "main_text"
},
{
"highlight": "In Medicaid, states are steadily outsourcing their programs to managed care companies like <em>Centene</em> to help reduce costs and improve care quality. Managed Medicaid penetration has increased meaningfully over the past two decades, and we expect further gains over time.",
"sentiment": 0.9517,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> holds the top market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, in Centene’s Medicare Advantage business, past missteps will result in losses next year, but we believe <em>Centene</em> can turn its Medicare Advantage segment around and generate positive earnings in the next few years.",
"sentiment": 0.8705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> currently trades for about 9x our estimate of normal earnings power, which we believe is a compelling value for a business that generates healthy returns on capital and is capable of growing EPS at a low double-digit rate.”\n\nOverall CNC ranks 7th on our list of the best health insurance stocks to buy.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Centene</em> <em>Corporation</em> (CNC): Do Hedge Funds Recommend This Health Insurance Stock Right Now?",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "d3e59955-ca95-49cd-aa2b-783494d5390e",
"title": "Is CVS Health Corporation (CVS) the Best Health Insurance Stock to Buy Now?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where CVS Health Corporation (NYSE:CV...",
"url": "https://www.insidermonkey.com/blog/is-cvs-health-corporation-cvs-the-best-health-insurance-stock-to-buy-now-1326727/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/21041848/CVS-insidermonkey-1695284326686.jpg",
"language": "en",
"published_at": "2024-07-27T02:13:00.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "BLK.MX",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797828,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS.MX",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 122.734985,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "BLK",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 10.797673,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 141.06207,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE:CVS</em>), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HRS.L",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 122.726105,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "0QZZ.L",
"name": "BlackRock, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 10.797423,
"sentiment_score": 0.6369,
"highlights": [
{
"highlight": "On another front, <em>BlackRock</em>, <em>Inc</em>. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVSH34.SA",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 122.80061,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "CVS.SN",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 122.7968,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
},
{
"symbol": "CVSCL.SN",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 122.7968,
"sentiment_score": 0.3522,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS)\n\nNumber of Hedge Fund Holders: 54\n\n<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "In early May, Argus revised its stock price target for <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, on May 23, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "According to the report, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established.",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Ariel Global Fund stated the following regarding <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS) in its first quarter 2024 investor letter:\n\n“We bought American healthcare company, <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Is <em>CVS</em> <em>Health</em> <em>Corporation</em> (CVS) the Best Health Insurance Stock to Buy Now?",
"sentiment": 0.6369,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "95eb0220-455a-40ec-965e-f6365df9326a",
"title": "Veja as companhias que divulgaram informações sobre JCP e dividendos na semana",
"description": "Publicado às 0h01 A seguir confira as companhias que divulgaram informações sobre […]",
"keywords": "",
"snippet": "Veja as companhias que divulgaram informações sobre JCP e dividendos na semana\n\nPublicado às 0h01\n\nA seguir confira as companhias que divulgaram informaçõe...",
"url": "https://financenews.com.br/2024/07/veja-as-companhias-que-divulgaram-informacoes-sobre-jcp-e-dividendos-na-semana-5/",
"image_url": "https://financenews.com.br/wp-content/uploads/2020/11/Dividendos-Juros-sobre-o-capital.jpg",
"language": "pt",
"published_at": "2024-07-27T02:43:03.000000Z",
"source": "financenews.com.br",
"relevance_score": null,
"entities": [
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.57219,
"sentiment_score": null,
"highlights": [
{
"highlight": "BDRs\n\nAlphabet, Nasdaq, Bank Of America, Pepsico, Blackrock, Equinor, Wells Fargo, <em>Merck</em> & Co, Visa, SL Green Realty, General Motors e outras companhias anunciaram anunciaram dividendos.",
"sentiment": 0.6369,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "04c505e1-d040-465d-9d5b-b101d391be3c",
"title": "Why Are Hedge Funds Bullish on HCA Healthcare, Inc. (HCA)?",
"description": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where HCA Healthcare, Inc.",
"keywords": "",
"snippet": "We recently compiled a list of the 10 Best Health Insurance Stocks to Buy. In this article, we are going to take a look at where HCA Healthcare, Inc. (NYSE:HCA)...",
"url": "https://www.insidermonkey.com/blog/why-are-hedge-funds-bullish-on-hca-healthcare-inc-hca-1326739/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/21041524/HCA-insidermonkey-1695284121488.jpg",
"language": "en",
"published_at": "2024-07-27T02:31:06.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "HCA.MX",
"name": "HCA Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 135.2063,
"sentiment_score": 0.488278,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA)\n\nNumber of Hedge Fund Holders: 72\n\nFounded in 1968, <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) is a leading healthcare provider known for its extensive network, owning and operating 182 hospitals and approximately 2,300 ambulatory care sites.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) had a notable first quarter in 2024, showcasing strong financial results and significant growth in inpatient admissions, surgeries, and emergency room visits. Although there was a decline in outpatient surgery revenue, the company’s adjusted earnings per share increased to $5.36, reflecting nearly a 9% rise.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "This revision, which considers the first-quarter performance and a perceived softening in the trend environment, led TD Cowen to adjust its projections for <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA)’s EBITDA in 2024 and 2025, as well as its 2025 enterprise value to EBITDA minus net corporate income target multiple.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "As of Q1 2024, 72 hedge funds held positions in <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) The fund with the largest stake was First Eagle Investment Management, holding 4.5 million shares, which comprised 3.41% of their portfolio.\n\nDiamond Hill Large Cap Strategy stated the following regarding <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "(NYSE:HCA) in its first quarter 2024 investor letter:\n\n“Among our top individual contributors in Q1 were American International Group (AIG) and <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA).",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Health care facilities operator <em>HCA</em> <em>Healthcare</em> benefited from a strong demand environment for hospitals in Q4, which is expected to continue into 2024 as nursing labor costs normalize and companies are able to improve margins tied to above-average physician costs.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "As a best-in-class operator with unique assets in favorable geographies, we believe the outlook for <em>HCA</em> <em>Healthcare</em> from here is favorable.”\n\nOverall HCA ranks 5th on our list of the best health insurance stocks to buy. You can visit 10 Best Health Insurance Stocks to Buy to see the other health insurance stocks that are on hedge funds’ radar.",
"sentiment": 0.9217,
"highlighted_in": "main_text"
},
{
"highlight": "Why Are Hedge Funds Bullish on <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (HCA)?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "HCA",
"name": "HCA Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 154.66869,
"sentiment_score": 0.488278,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>)\n\nNumber of Hedge Fund Holders: 72\n\nFounded in 1968, <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>) is a leading healthcare provider known for its extensive network, owning and operating 182 hospitals and approximately 2,300 ambulatory care sites.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>) had a notable first quarter in 2024, showcasing strong financial results and significant growth in inpatient admissions, surgeries, and emergency room visits. Although there was a decline in outpatient surgery revenue, the company’s adjusted earnings per share increased to $5.36, reflecting nearly a 9% rise.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "This revision, which considers the first-quarter performance and a perceived softening in the trend environment, led TD Cowen to adjust its projections for <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>)’s EBITDA in 2024 and 2025, as well as its 2025 enterprise value to EBITDA minus net corporate income target multiple.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "As of Q1 2024, 72 hedge funds held positions in <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>) The fund with the largest stake was First Eagle Investment Management, holding 4.5 million shares, which comprised 3.41% of their portfolio.\n\nDiamond Hill Large Cap Strategy stated the following regarding <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NYSE:HCA</em>) in its first quarter 2024 investor letter:\n\n“Among our top individual contributors in Q1 were American International Group (AIG) and <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (<em>NYSE:HCA</em>).",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Health care facilities operator <em>HCA</em> <em>Healthcare</em> benefited from a strong demand environment for hospitals in Q4, which is expected to continue into 2024 as nursing labor costs normalize and companies are able to improve margins tied to above-average physician costs.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "As a best-in-class operator with unique assets in favorable geographies, we believe the outlook for <em>HCA</em> <em>Healthcare</em> from here is favorable.”\n\nOverall HCA ranks 5th on our list of the best health insurance stocks to buy. You can visit 10 Best Health Insurance Stocks to Buy to see the other health insurance stocks that are on hedge funds’ radar.",
"sentiment": 0.9217,
"highlighted_in": "main_text"
},
{
"highlight": "Why Are Hedge Funds Bullish on <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (HCA)?",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "H1CA34.SA",
"name": "HCA Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 135.20268,
"sentiment_score": 0.488278,
"highlights": [
{
"highlight": "In this article, we are going to take a look at where <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) stands against the other health insurance stocks.\n\nThe Healthcare Market: What does the future hold?\n\n2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA)\n\nNumber of Hedge Fund Holders: 72\n\nFounded in 1968, <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) is a leading healthcare provider known for its extensive network, owning and operating 182 hospitals and approximately 2,300 ambulatory care sites.",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "<em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) had a notable first quarter in 2024, showcasing strong financial results and significant growth in inpatient admissions, surgeries, and emergency room visits. Although there was a decline in outpatient surgery revenue, the company’s adjusted earnings per share increased to $5.36, reflecting nearly a 9% rise.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "This revision, which considers the first-quarter performance and a perceived softening in the trend environment, led TD Cowen to adjust its projections for <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA)’s EBITDA in 2024 and 2025, as well as its 2025 enterprise value to EBITDA minus net corporate income target multiple.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "As of Q1 2024, 72 hedge funds held positions in <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA) The fund with the largest stake was First Eagle Investment Management, holding 4.5 million shares, which comprised 3.41% of their portfolio.\n\nDiamond Hill Large Cap Strategy stated the following regarding <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "(NYSE:HCA) in its first quarter 2024 investor letter:\n\n“Among our top individual contributors in Q1 were American International Group (AIG) and <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (NYSE:HCA).",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Health care facilities operator <em>HCA</em> <em>Healthcare</em> benefited from a strong demand environment for hospitals in Q4, which is expected to continue into 2024 as nursing labor costs normalize and companies are able to improve margins tied to above-average physician costs.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "As a best-in-class operator with unique assets in favorable geographies, we believe the outlook for <em>HCA</em> <em>Healthcare</em> from here is favorable.”\n\nOverall HCA ranks 5th on our list of the best health insurance stocks to buy. You can visit 10 Best Health Insurance Stocks to Buy to see the other health insurance stocks that are on hedge funds’ radar.",
"sentiment": 0.9217,
"highlighted_in": "main_text"
},
{
"highlight": "Why Are Hedge Funds Bullish on <em>HCA</em> <em>Healthcare</em>, <em>Inc</em>. (HCA)?",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "26b2f45d-e331-46ca-b4ae-e332a2cedd8b",
"title": "Q1 results today: ICICI Bank, Dr Reddy’s Lab, MCX, Finolex Industries, Punjab National Bank & more to report earnings",
"description": "Q1 results today: At least 30 companies including ICICI Bank, Dr Reddy’s Lab, MCX, Finolex Industries, Punjab National Bank, IDFC First Bank, Jaiprakash Ventures, SBFC Finance, and Transport Corporation of India will declare their FY25 earnings on July 27.",
"keywords": "markets, Q1 earnings, Q1 results, earnings, results, India, companies, first quarter, earnings report, ICICI Bank, Dr Reddys Laboratory, MCX, Finolex Industries",
"snippet": "Q1 results today on July 27: At least 30 companies are scheduled to release their first quarter financial results (Q1FY25) today, on Saturday, July 27.\n\nThe fir...",
"url": "https://www.livemint.com/companies/company-results/q1-results-today-july-27-icici-bank-dr-reddys-lab-mcx-finolex-industries-punjab-national-bank-idfc-first-bank-earnings-11722045137183.html",
"image_url": "https://images.livemint.com/img/2024/07/27/1600x900/q1_results_today_July_27_ICICI_Bank_Dr_Reddys_Lab_1722046297809_1722046298065.jpg",
"language": "en",
"published_at": "2024-07-27T02:18:25.000000Z",
"source": "livemint.com",
"relevance_score": null,
"entities": [
{
"symbol": "DRREDDY.NS",
"name": "Dr. Reddy's Laboratories Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 27.581833,
"sentiment_score": -0.11315,
"highlights": [
{
"highlight": "First Bank, Jaiprakash Power Ventures, Jammu and Kashmir Bank, SBFC Finance, Transport Corporation of India, IFB Industries, Spandana Sphoorty Financial, Shaily Engineering Plastics, Meghmani Organics, Vishal Fabrics, Smruti Organics Limited, Premco Global, Oswal Yarns, 3p Land Holdings, Sacheta Metals, IEC Education, ICICI Bank, Finolex Industries, <em>Dr</em>",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Reddy's</em> <em>Laboratories</em>, Anant Raj, Genus Power Infrastructures, Alankit, Asahi Songwon Colors, Alkali Metals, Astal Laboratories, Gujarat Cotex, and others are among the 30 companies expected to report their Q1FY25 earnings reports today, on July 27.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "4737b82d-07f0-4e0b-83a6-0e52a1f790f1",
"title": "Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement By Investing.com",
"description": "Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement",
"keywords": "",
"snippet": "VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the Company), a biopharmaceutical company committed to a...",
"url": "https://www.investing.com/news/press-releases/rakovina-therapeutics-closes-previously-announced-oversubscribed-private-placement-93CH-3540230",
"image_url": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
"language": "en",
"published_at": "2024-07-27T01:36:04.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "RKV.V",
"name": "Rakovina Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 105.30929,
"sentiment_score": -0.0256,
"highlights": [
{
"highlight": "VANCOUVER, British Columbia, July 26, 2024 (GLOBE NEWSWIRE) -- <em>Rakovina</em> <em>Therapeutics</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Rakovina</em> <em>Therapeutics</em>' goal is to advance one or more next-generation DDR drug candidates into human clinical trials in collaboration with pharmaceutical partners.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Rakovina</em> <em>Therapeutics</em> <em>Inc</em>.\n\n<em>Rakovina</em> <em>Therapeutics</em> <em>Inc</em>. is focused on the development of new cancer treatments based on novel DNA-damage response technologies.",
"sentiment": -0.128,
"highlighted_in": "main_text"
},
{
"highlight": "Gostin [email protected] 775-391-0213\n\nSource: <em>Rakovina</em> <em>Therapeutics</em> <em>Inc</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Rakovina</em> <em>Therapeutics</em> Closes Previously Announced Over-subscribed Private Placement By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "847656d7-c96e-4552-b67b-b11f9105f713",
"title": "Q1 2025 Laurus Labs Ltd Earnings Call Transcript",
"description": "Jul 25, 2024 / 11:30AM GMTOperator Ladies and gentlemen, good day, and welcome to Laurus Labs Limited Q1 FY25 earnings conference call hosted by Antique Stock B",
"keywords": "GuruFocus, Article, News, GuruFocus Research, BOM:540222",
"snippet": "Jul 25, 2024 / 11:30AM GMT\n\nOperator\n\n\n\nLadies and gentlemen, good day, and welcome to Laurus Labs Limited Q1 FY25 earnings conference call hosted by Antique St...",
"url": "https://www.gurufocus.com/news/2483674/q1-2025-laurus-labs-ltd-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-07-27T01:09:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LAURUSLABS.NS",
"name": "Laurus Labs Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 101.732574,
"sentiment_score": 0.60255,
"highlights": [
{
"highlight": "Jul 25, 2024 / 11:30AM GMT\n\nOperator\n\n\n\nLadies and gentlemen, good day, and welcome to <em>Laurus</em> <em>Labs</em> <em>Limited</em> Q1 FY25 earnings conference call hosted by Antique Stock Broking. (Operator instructions) Please note that this conference is being recorded. I'll hand the conference over to Mr. Monish Shah from Antique Stock Broking.",
"sentiment": 0.886,
"highlighted_in": "main_text"
},
{
"highlight": "Good evening, everyone, and welcome to <em>Laurus</em> <em>Labs</em> Q1 FY25 earnings conference call. Today we have with us Dr. Satyanarayana Chava, Founder and CEO, and Mr. VV Ravi Kumar, Executive Director and CFO and Vivek from the IR team. On behalf of Antique Stockbroking, I thank Laurus management for giving us the opportunity to host this call.",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "Satyanarayana Chava - <em>Laurus</em> <em>Labs</em> Ltd - Chief Executive Officer, Executive Director\n\n\n\nThank you, Monish, for your introduction. Thank you all for joining us on our Q1 FY25 results",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2025 <em>Laurus</em> <em>Labs</em> Ltd Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "LAURUSLABS.BO",
"name": "Laurus Labs Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 101.71736,
"sentiment_score": 0.60255,
"highlights": [
{
"highlight": "Jul 25, 2024 / 11:30AM GMT\n\nOperator\n\n\n\nLadies and gentlemen, good day, and welcome to <em>Laurus</em> <em>Labs</em> <em>Limited</em> Q1 FY25 earnings conference call hosted by Antique Stock Broking. (Operator instructions) Please note that this conference is being recorded. I'll hand the conference over to Mr. Monish Shah from Antique Stock Broking.",
"sentiment": 0.886,
"highlighted_in": "main_text"
},
{
"highlight": "Good evening, everyone, and welcome to <em>Laurus</em> <em>Labs</em> Q1 FY25 earnings conference call. Today we have with us Dr. Satyanarayana Chava, Founder and CEO, and Mr. VV Ravi Kumar, Executive Director and CFO and Vivek from the IR team. On behalf of Antique Stockbroking, I thank Laurus management for giving us the opportunity to host this call.",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "Satyanarayana Chava - <em>Laurus</em> <em>Labs</em> Ltd - Chief Executive Officer, Executive Director\n\n\n\nThank you, Monish, for your introduction. Thank you all for joining us on our Q1 FY25 results",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2025 <em>Laurus</em> <em>Labs</em> Ltd Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "b8d641ba-8761-44cc-8b78-c1780bb06a57",
"title": "Q1 2025 Glenmark Life Sciences Ltd Earnings Call Transcript",
"description": "Jul 25, 2024 / NTS GMTOperator Good morning, ladies and gentlemen. Welcome to the Glenmark Life Sciences Q1 FY25 earnings conference call. (Operator Instruction",
"keywords": "GuruFocus, Article, News, GuruFocus Research, BOM:543322",
"snippet": "Jul 25, 2024 / NTS GMT\n\nOperator\n\n\n\nGood morning, ladies and gentlemen. Welcome to the Glenmark Life Sciences Q1 FY25 earnings conference call. (Operator Instru...",
"url": "https://www.gurufocus.com/news/2483650/q1-2025-glenmark-life-sciences-ltd-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-07-27T00:05:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GLS.NS",
"name": "Glenmark Life Sciences Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 120.411224,
"sentiment_score": 0.562533,
"highlights": [
{
"highlight": "Welcome to the <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Q1 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.\n\n\n\nI now hand the conference over to Ms. Soumi Rao from <em>Glenmark</em> <em>Life</em> <em>Sciences</em>. Thank you, and over to you, ma'am.",
"sentiment": 0.875,
"highlighted_in": "main_text"
},
{
"highlight": "Soumi Rao - <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Ltd - General Manager, Corporate Communications\n\n\n\nThank you. Good morning, everyone. I welcome you all to this early morning earnings call of <em>Glenmark</em> <em>Life</em> <em>Sciences</em> <em>Limited</em> for the quarter ended June 30, 2024. From <em>Glenmark</em> <em>Life</em> <em>Sciences</em>, we have with us Dr. Yasir Rawjee, our Managing Director and CEO, and Mr.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2025 <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Ltd Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "GLS.BO",
"name": "Glenmark Life Sciences Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "N/A",
"match_score": 120.4068,
"sentiment_score": 0.562533,
"highlights": [
{
"highlight": "Welcome to the <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Q1 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.\n\n\n\nI now hand the conference over to Ms. Soumi Rao from <em>Glenmark</em> <em>Life</em> <em>Sciences</em>. Thank you, and over to you, ma'am.",
"sentiment": 0.875,
"highlighted_in": "main_text"
},
{
"highlight": "Soumi Rao - <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Ltd - General Manager, Corporate Communications\n\n\n\nThank you. Good morning, everyone. I welcome you all to this early morning earnings call of <em>Glenmark</em> <em>Life</em> <em>Sciences</em> <em>Limited</em> for the quarter ended June 30, 2024. From <em>Glenmark</em> <em>Life</em> <em>Sciences</em>, we have with us Dr. Yasir Rawjee, our Managing Director and CEO, and Mr.",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2025 <em>Glenmark</em> <em>Life</em> <em>Sciences</em> Ltd Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "a7cfd907-0438-4aa6-831c-af94f4a62fe7",
"title": "Minerals Technologies Inc. (MTX) Q2 2024 Earnings Call Transcript",
"description": "Minerals Technologies Inc. (NYSE:NYSE:MTX) Q2 2024 Earnings Conference Call July 26, 2024 11:00 AM ETCompany ParticipantsLydia Kopylova - Head, IRDoug...",
"keywords": "",
"snippet": "Minerals Technologies Inc. (NYSE:MTX) Q2 2024 Earnings Conference Call July 26, 2024 11:00 AM ET\n\nCompany Participants\n\nLydia Kopylova - Head, IR\n\nDoug Dietrich...",
"url": "https://seekingalpha.com/article/4707345-minerals-technologies-inc-mtx-q2-2024-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-07-26T21:13:07.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MTX",
"name": "Minerals Technologies Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 124.686554,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Minerals</em> <em>Technologies</em> <em>Inc</em>. (<em>NYSE:MTX</em>) Q2 2024 Earnings Conference Call July 26, 2024 11:00 AM ET\n\nCompany Participants\n\nLydia Kopylova - Head, IR\n\nDoug Dietrich - Chairman and CEO\n\nErik Aldag - CFO\n\nD.J.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Minerals</em> <em>Technologies</em> <em>Inc</em>. (MTX) Q2 2024 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "MLKRI.PA",
"name": "Well SA",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Financial Services",
"match_score": 8.293724,
"sentiment_score": 0.60981,
"highlights": [
{
"highlight": "For the first half, our operating margin was 15.1%, <em>well</em> above the 14% interim margin target we set for 2024. You can see in the operating income bridge that volume and mix increased income by $3 million, which is net of the impact of the deconsolidation of BMI last year.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "For the first half, our operating margin was 15.1%, <em>well</em> above the 14% interim margin target we set for 2024. You can see in the operating income bridge that volume mix increased income by $3 million, which is net of the impact of the deconsolidation of BMI last year.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "In short, the business is performing <em>well</em>. And as a result, operating margin has improved significantly, up 370 basis points from prior year to 15.4% of sales.\n\nLooking ahead to the third quarter, we expect year-over-year growth for Household & Personal Care in the mid-single-digit range.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "Segment operating income was $45 million, up 16% over last year, driven by higher volumes and a favorable product mix in High-Temperature Technologies, as <em>well</em> as disciplined pricing and cost control. Operating margin was 17.4% of sales, up 270 basis points from prior year.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "With a more normalized product mix as <em>well</em> as some seasonally higher energy costs, we're expecting operating income between $77 million and $80 million, and operating margin remaining strong at close to 15%. And we expect EPS between $1.50 and $1.55.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Well</em>, did you hear anything I said, Dan?\n\nDaniel Moore\n\nI heard it all. So hopefully, others did as <em>well</em>. Maybe start with consumer. A lot of consumer, more discretionary businesses, had a tougher time in Q2. Your consumer business is held up really <em>well</em>. Feeling any sort of pinch at all in those businesses, just from maybe a tougher environment?",
"sentiment": 0.7581,
"highlighted_in": "main_text"
},
{
"highlight": "And so, we want to be there to help them, and we're <em>well</em> aligned to meet their needs.\n\nDoug Dietrich\n\nAnd Dan, as you know, these are set up, as Brett mentioned kind of five-year contracts that provide not only the equipment either as a capital sale or a lease, but then the refractory through it.",
"sentiment": 0.2144,
"highlighted_in": "main_text"
},
{
"highlight": "And it's coming in that kind of ratio as <em>well</em>. And as we mentioned, we think there's more to go as these higher-margin products continue to grow.\n\nDavid Silver\n\nOkay. Very good. Thanks for the color there. I did want to ask you a little bit more, if I could, about FLUORO-SORB.",
"sentiment": 0.8197,
"highlighted_in": "main_text"
},
{
"highlight": "So that's also contributing to the volume growth as <em>well</em>.\n\nSo one more quarter for the comparisons of BMI, steady growth coming from the paper and packaging satellites, Lucerne Valley continues to perform quite <em>well</em>. And the pipeline for the paper business is extremely strong.",
"sentiment": 0.83,
"highlighted_in": "main_text"
},
{
"highlight": "And so the long-term looks pretty strong as <em>well</em>.\n\nDavid Silver\n\nIt's great color. Thanks very much.\n\nD. J. Monagle\n\nCertainly.\n\nDoug Dietrich\n\nThanks David.\n\nOperator\n\nWe will take our next question from Mike Harrison with Seaport Research Partners.\n\nMike Harrison\n\nHi, guys.",
"sentiment": 0.9571,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MLAHC.PA",
"name": "@Health SA",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Healthcare",
"match_score": 6.534586,
"sentiment_score": 0.7793,
"highlights": [
{
"highlight": "We've expanded our Consumer & Specialties business - consumer specialty businesses into higher-margin growth markets like animal <em>health</em>, personal care and oil purification, and invested in new natural ingredient technologies that are aligned with macro consumer trends.",
"sentiment": 0.8689,
"highlighted_in": "main_text"
},
{
"highlight": "Meanwhile, we saw higher sales in several high-margin consumer applications such as personal care, fabric care and animal <em>health</em>\n\nIn Specialty Additives, sales were 4% higher on an underlying basis.",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "It's coming from animal <em>health</em>, it's coming from these personal care products.\n\nIt's coming from bleaching or - these are higher-margin products that we've invested in over the past few years. The cat litter business is becoming, as we've integrated and invested in cost reduction, a higher-margin business as well, which is now steadily growing.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MLMAD.PA",
"name": "Made SA",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "Technology",
"match_score": 6.505496,
"sentiment_score": 0.764925,
"highlights": [
{
"highlight": "As a reminder, some of the statements <em>made</em> during this call may constitute forward-looking statements within the meaning of the federal securities laws. Please note the cautionary language about forward-looking statements contained in our earnings release and on the slides.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "I want to highlight for you some of the significant changes we've <em>made</em> in each business, the new positions we've created, and why we are confident we can, not only sustain, but strengthen our performance going forward.\n\nLet's start with the consumer side of the company.",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "We've <em>made</em> tremendous progress integrating the acquired parts and optimizing it into a global business platform, and over the next couple of months, we'll be launching a new global brand for this business, to reflect this integration and provide a unified reference for our customers.",
"sentiment": 0.8255,
"highlighted_in": "main_text"
},
{
"highlight": "And so there's - it's mostly through the construction industry, but it's also just in general great performance by that plant and some product modifications that we've <em>made</em> that meet the market needs. So that's also contributing to the volume growth as well.",
"sentiment": 0.9136,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MLWEL.PA",
"name": "Well SA",
"exchange": null,
"exchange_long": null,
"country": "fr",
"type": "equity",
"industry": "N/A",
"match_score": 8.293608,
"sentiment_score": 0.60981,
"highlights": [
{
"highlight": "For the first half, our operating margin was 15.1%, <em>well</em> above the 14% interim margin target we set for 2024. You can see in the operating income bridge that volume and mix increased income by $3 million, which is net of the impact of the deconsolidation of BMI last year.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "For the first half, our operating margin was 15.1%, <em>well</em> above the 14% interim margin target we set for 2024. You can see in the operating income bridge that volume mix increased income by $3 million, which is net of the impact of the deconsolidation of BMI last year.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "In short, the business is performing <em>well</em>. And as a result, operating margin has improved significantly, up 370 basis points from prior year to 15.4% of sales.\n\nLooking ahead to the third quarter, we expect year-over-year growth for Household & Personal Care in the mid-single-digit range.",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "Segment operating income was $45 million, up 16% over last year, driven by higher volumes and a favorable product mix in High-Temperature Technologies, as <em>well</em> as disciplined pricing and cost control. Operating margin was 17.4% of sales, up 270 basis points from prior year.",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "With a more normalized product mix as <em>well</em> as some seasonally higher energy costs, we're expecting operating income between $77 million and $80 million, and operating margin remaining strong at close to 15%. And we expect EPS between $1.50 and $1.55.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Well</em>, did you hear anything I said, Dan?\n\nDaniel Moore\n\nI heard it all. So hopefully, others did as <em>well</em>. Maybe start with consumer. A lot of consumer, more discretionary businesses, had a tougher time in Q2. Your consumer business is held up really <em>well</em>. Feeling any sort of pinch at all in those businesses, just from maybe a tougher environment?",
"sentiment": 0.7581,
"highlighted_in": "main_text"
},
{
"highlight": "And so, we want to be there to help them, and we're <em>well</em> aligned to meet their needs.\n\nDoug Dietrich\n\nAnd Dan, as you know, these are set up, as Brett mentioned kind of five-year contracts that provide not only the equipment either as a capital sale or a lease, but then the refractory through it.",
"sentiment": 0.2144,
"highlighted_in": "main_text"
},
{
"highlight": "And it's coming in that kind of ratio as <em>well</em>. And as we mentioned, we think there's more to go as these higher-margin products continue to grow.\n\nDavid Silver\n\nOkay. Very good. Thanks for the color there. I did want to ask you a little bit more, if I could, about FLUORO-SORB.",
"sentiment": 0.8197,
"highlighted_in": "main_text"
},
{
"highlight": "So that's also contributing to the volume growth as <em>well</em>.\n\nSo one more quarter for the comparisons of BMI, steady growth coming from the paper and packaging satellites, Lucerne Valley continues to perform quite <em>well</em>. And the pipeline for the paper business is extremely strong.",
"sentiment": 0.83,
"highlighted_in": "main_text"
},
{
"highlight": "And so the long-term looks pretty strong as <em>well</em>.\n\nDavid Silver\n\nIt's great color. Thanks very much.\n\nD. J. Monagle\n\nCertainly.\n\nDoug Dietrich\n\nThanks David.\n\nOperator\n\nWe will take our next question from Mike Harrison with Seaport Research Partners.\n\nMike Harrison\n\nHi, guys.",
"sentiment": 0.9571,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "919f5e62-592c-44b6-8acb-6dcf9aae7155",
"title": "UCB SA (UCBJF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Increased Investments",
"description": "Net Sales Growth: +11% or +13% at constant exchange rates.Adjusted EBITDA: 23%, slightly in decline versus last year.BIMZELX Sales (US): EUR85 million for the",
"keywords": "GuruFocus, Article, News, GuruFocus Research, UCBJF",
"snippet": "Release Date: July 25, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nPositive Points\n\nUCB SA (UCBJ...",
"url": "https://www.gurufocus.com/news/2483673/ucb-sa-ucbjf-q2-2024-earnings-call-transcript-highlights-strong-sales-growth-amid-increased-investments",
"image_url": "https://static.gurufocus.com/logos/0C00000WQ0.png?5",
"language": "en",
"published_at": "2024-07-27T01:00:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "UCBJY",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.28839,
"sentiment_score": 0.47264,
"highlights": [
{
"highlight": "Positive Points\n\n<em>UCB</em> <em>SA</em> (UCBJF, Financial) reported a significant turnaround in net sales, achieving a growth of 11% or 13% at constant exchange rates, compared to a decline of 12% or 14% the previous year.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) achieved five new approvals in various regions, including BIMZELX for hidradenitis suppurativa in Europe and ankylosing spondylarthritis in China.\n\nThe company has a strong pipeline with 10 new patient populations in 10 projects expected to deliver significant news flow in the second half of 2024.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) improved its ESG rating by increasing product availability in low and medium-income countries and enhancing access to its products, reaching 82% in June.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Negative Points\n\nDespite the positive sales growth, <em>UCB</em> <em>SA</em> (UCBJF) reported a decline in adjusted EBITDA to 23%, attributed to substantial investments behind new product launches.",
"sentiment": -0.2644,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Increased Investments",
"sentiment": 0.7906,
"highlighted_in": "title"
}
]
},
{
"symbol": "UCBJF",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 125.620865,
"sentiment_score": 0.47264,
"highlights": [
{
"highlight": "Positive Points\n\n<em>UCB</em> <em>SA</em> (<em>UCBJF</em>, Financial) reported a significant turnaround in net sales, achieving a growth of 11% or 13% at constant exchange rates, compared to a decline of 12% or 14% the previous year.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (<em>UCBJF</em>) achieved five new approvals in various regions, including BIMZELX for hidradenitis suppurativa in Europe and ankylosing spondylarthritis in China.\n\nThe company has a strong pipeline with 10 new patient populations in 10 projects expected to deliver significant news flow in the second half of 2024.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (<em>UCBJF</em>) improved its ESG rating by increasing product availability in low and medium-income countries and enhancing access to its products, reaching 82% in June.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Negative Points\n\nDespite the positive sales growth, <em>UCB</em> <em>SA</em> (<em>UCBJF</em>) reported a decline in adjusted EBITDA to 23%, attributed to substantial investments behind new product launches.",
"sentiment": -0.2644,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (<em>UCBJF</em>) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Increased Investments",
"sentiment": 0.7906,
"highlighted_in": "title"
}
]
},
{
"symbol": "UCB.BR",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "be",
"type": "equity",
"industry": "Healthcare",
"match_score": 84.19627,
"sentiment_score": 0.47264,
"highlights": [
{
"highlight": "Positive Points\n\n<em>UCB</em> <em>SA</em> (UCBJF, Financial) reported a significant turnaround in net sales, achieving a growth of 11% or 13% at constant exchange rates, compared to a decline of 12% or 14% the previous year.",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) achieved five new approvals in various regions, including BIMZELX for hidradenitis suppurativa in Europe and ankylosing spondylarthritis in China.\n\nThe company has a strong pipeline with 10 new patient populations in 10 projects expected to deliver significant news flow in the second half of 2024.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) improved its ESG rating by increasing product availability in low and medium-income countries and enhancing access to its products, reaching 82% in June.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "Negative Points\n\nDespite the positive sales growth, <em>UCB</em> <em>SA</em> (UCBJF) reported a decline in adjusted EBITDA to 23%, attributed to substantial investments behind new product launches.",
"sentiment": -0.2644,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UCB</em> <em>SA</em> (UCBJF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Increased Investments",
"sentiment": 0.7906,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "43bc5388-5644-4e39-ab2c-26ef0daeb970",
"title": "Half Year 2024 Roche Holding AG Earnings Call Transcript",
"description": "Jul 25, 2024 / 12:00PM GMTThomas Schinecker - Roche Holding AG - Chief Executive Officer - Roche Group Thank you very much, and hello to everyone. Good morning,",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:RHHBF",
"snippet": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - Roche Holding AG - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good mor...",
"url": "https://www.gurufocus.com/news/2483598/half-year-2024-roche-holding-ag-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-07-26T22:07:19.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "RHHBY",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.22334,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "RHHBF",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.22334,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "RHHVF",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.22128,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "ROGN.MX",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.2109,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0TDF.L",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 142.20789,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0QQ6.L",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 142.20209,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "ROG.SW",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.20052,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "RO.SW",
"name": "Roche Holding AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.20052,
"sentiment_score": 0.43895,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nThomas Schinecker - <em>Roche</em> <em>Holding</em> <em>AG</em> - Chief Executive Officer - Roche Group\n\n\n\nThank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.\n\n\n\nNow, let me take you through this slide first.",
"sentiment": 0.8779,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Roche</em> <em>Holding</em> <em>AG</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "785f9b1a-4310-435c-b499-4612d0f71970",
"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, Roblox, Gritstone, and Rivian and Encourages Investors to Contact the Firm",
"description": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...",
"keywords": "Bragar Eagel & Squire, Scotts, SMG, Roblox, RBLX, Gritstone, GRTS, Rivian, RIVN, securities, class action, stockholder rights, legal, lawyer, litigate, lawsuit, complaint, a, Class Action",
"snippet": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actio...",
"url": "https://www.globenewswire.com/news-release/2024/07/27/2919921/0/en/Bragar-Eagel-Squire-P-C-Reminds-Investors-That-Class-Action-Lawsuits-Have-Been-Filed-Against-Scotts-Roblox-Gritstone-and-Rivian-and-Encourages-Investors-to-Contact-the-Firm.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/29481954-f2ff-4756-b5a9-d982a6497bd0",
"language": "en",
"published_at": "2024-07-27T01:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "GRTS",
"name": "Gritstone bio, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.99801,
"sentiment_score": -0.175567,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of The Scotts Miracle-Gro Company (NYSE: SMG), Roblox Corporation (NYSE: RBLX), <em>Gritstone</em> <em>bio</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>GRTS</em>), and Rivian Automotive, Inc. (NASDAQ: RIVN).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Roblox class action go to: https://bespc.com/cases/RBLX\n\n<em>Gritstone</em> <em>bio</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>GRTS</em>)\n\nClass Period: March 9, 2023 - February 29, 2024\n\nLead Plaintiff Deadline: August 6, 2024\n\nGritstone, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.",
"sentiment": -0.5267,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "785f9b1a-4310-435c-b499-4612d0f71970",
"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, Roblox, Gritstone, and Rivian and Encourages Investors to Contact the Firm",
"description": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...",
"keywords": "Bragar Eagel & Squire, Scotts, SMG, Roblox, RBLX, Gritstone, GRTS, Rivian, RIVN, securities, class action, stockholder rights, legal, lawyer, litigate, lawsuit, complaint, a, Class Action",
"snippet": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actio...",
"url": "https://www.globenewswire.com/news-release/2024/07/27/2919921/0/en/Bragar-Eagel-Squire-P-C-Reminds-Investors-That-Class-Action-Lawsuits-Have-Been-Filed-Against-Scotts-Roblox-Gritstone-and-Rivian-and-Encourages-Investors-to-Contact-the-Firm.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/29481954-f2ff-4756-b5a9-d982a6497bd0",
"language": "en",
"published_at": "2024-07-27T01:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "GRTS",
"name": "Gritstone bio, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.99801,
"sentiment_score": -0.175567,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of The Scotts Miracle-Gro Company (NYSE: SMG), Roblox Corporation (NYSE: RBLX), <em>Gritstone</em> <em>bio</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>GRTS</em>), and Rivian Automotive, Inc. (NASDAQ: RIVN).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Roblox class action go to: https://bespc.com/cases/RBLX\n\n<em>Gritstone</em> <em>bio</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>GRTS</em>)\n\nClass Period: March 9, 2023 - February 29, 2024\n\nLead Plaintiff Deadline: August 6, 2024\n\nGritstone, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.",
"sentiment": -0.5267,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SMG",
"name": "The Scotts Miracle-Gro Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Basic Materials",
"match_score": 62.69589,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>The</em> <em>Scotts</em> <em>Miracle</em>-<em>Gro</em> <em>Company</em> (<em>NYSE</em>: <em>SMG</em>), Roblox Corporation (NYSE: RBLX), Gritstone bio, Inc. (NASDAQ: GRTS), and Rivian Automotive, Inc. (NASDAQ: RIVN).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>The</em> <em>Scotts</em> <em>Miracle</em>-<em>Gro</em> <em>Company</em> (<em>NYSE</em>: <em>SMG</em>)\n\nClass Period: November 3, 2021 - August 1, 2023\n\nLead Plaintiff Deadline: August 2, 2024\n\nScotts produces various lawn, garden, and agricultural products for both consumer and professional purposes. It is also the world’s largest marketer of branded consumer products for lawn and garden care.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "RBLX",
"name": "Roblox Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 57.70534,
"sentiment_score": -0.050029,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of The Scotts Miracle-Gro Company (NYSE: SMG), <em>Roblox</em> <em>Corporation</em> (<em>NYSE</em>: <em>RBLX</em>), Gritstone bio, Inc. (NASDAQ: GRTS), and Rivian Automotive, Inc. (NASDAQ: RIVN).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Scotts class action go to: https://bespc.com/cases/SMG\n\n<em>Roblox</em> <em>Corporation</em> (<em>NYSE</em>: <em>RBLX</em>)\n\nClass Period: November 15, 2023 - May 8, 2024\n\nLead Plaintiff Deadline: August 9, 2024\n\n<em>Roblox</em> is an online entertainment publisher and distributor which also sells advertising space on those platforms.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Roblox</em> class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants created the false impression that they possessed reliable information pertaining to Roblox’s projected revenue outlook and anticipated bookings growth, due largely to expansion in Roblox",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "According to the <em>Roblox</em> class action lawsuit, in fact, <em>Roblox</em> faced difficulty converting daily active users into bookings and eventually blamed the very technology and platform growth <em>Roblox</em> lauded as revolutionary and revenue-generating for this bookings problem.",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Roblox</em> class action lawsuit further alleges that on May 8, 2024, <em>Roblox</em> revised down its fiscal year 2024 bookings guidance to $4.0 billion to $4.14 billion and revised down total revenue to $3.30 billion to $3.40 billion.\n\nOn this news, the price of <em>Roblox</em> stock fell more than 22%, according to the complaint.",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>Roblox</em> class action go to: https://bespc.com/cases/<em>RBLX</em>\n\nGritstone bio, Inc.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, <em>Roblox</em>, Gritstone, and Rivian and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "0L45.L",
"name": "The Scotts Miracle-Gro Company",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 45.88765,
"sentiment_score": 0.24695,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>The</em> <em>Scotts</em> <em>Miracle</em>-<em>Gro</em> <em>Company</em> (NYSE: SMG), Roblox Corporation (NYSE: RBLX), Gritstone bio, Inc. (NASDAQ: GRTS), and Rivian Automotive, Inc. (NASDAQ: RIVN).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>The</em> <em>Scotts</em> <em>Miracle</em>-<em>Gro</em> <em>Company</em> (NYSE: SMG)\n\nClass Period: November 3, 2021 - August 1, 2023\n\nLead Plaintiff Deadline: August 2, 2024\n\nScotts produces various lawn, garden, and agricultural products for both consumer and professional purposes. It is also the world’s largest marketer of branded consumer products for lawn and garden care.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "406247c6-5686-4cc9-8886-994e7aaf51ae",
"title": "DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of DexCom Stockholders and Encourages Investors to Contact the Firm",
"description": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating...",
"keywords": "Bragar Eagel & Squire, DexCom, DXCM, securities, class action, stockholder rights, legal, lawyer, lawsuit, litigate, investigation, share, stock, investor, invest, a, Class Action",
"snippet": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims ...",
"url": "https://www.globenewswire.com/news-release/2024/07/27/2919924/0/en/DEXCOM-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-DexCom-Inc-on-Behalf-of-DexCom-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/29481954-f2ff-4756-b5a9-d982a6497bd0",
"language": "en",
"published_at": "2024-07-27T01:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "DXCM",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 101.81426,
"sentiment_score": 0.299233,
"highlights": [
{
"highlight": "., a nationally recognized stockholder rights law firm, is investigating potential claims against <em>DexCom</em>, <em>Inc</em>. (“<em>DexCom</em>” or the “Company”) (<em>NASDAQ</em>: <em>DXCM</em>) on behalf of <em>DexCom</em> stockholders. Our investigation concerns whether <em>DexCom</em> has violated the federal securities laws and/or engaged in other unlawful business practices.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On July 25, 2024, after the closure of market trading, <em>DexCom</em> issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>DexCom</em> revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to \"certain unique items impacting 2024 seasonality,\" which have been identified as factors influencing the Company’s financial outlook.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Following this news, <em>DexCom</em> stock was trading down 39% during pre-market trading on July 26, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you purchased or otherwise acquired <em>DexCom</em> shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DEXCOM</em> ALERT: Bragar Eagel & Squire, P.C. is Investigating <em>DexCom</em>, <em>Inc</em>. on Behalf of <em>DexCom</em> Stockholders and Encourages Investors to Contact the Firm",
"sentiment": 0.7034,
"highlighted_in": "title"
}
]
},
{
"symbol": "DC4.DE",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.999374,
"sentiment_score": 0.299233,
"highlights": [
{
"highlight": "., a nationally recognized stockholder rights law firm, is investigating potential claims against <em>DexCom</em>, <em>Inc</em>. (“<em>DexCom</em>” or the “Company”) (NASDAQ: DXCM) on behalf of <em>DexCom</em> stockholders. Our investigation concerns whether <em>DexCom</em> has violated the federal securities laws and/or engaged in other unlawful business practices.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On July 25, 2024, after the closure of market trading, <em>DexCom</em> issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>DexCom</em> revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to \"certain unique items impacting 2024 seasonality,\" which have been identified as factors influencing the Company’s financial outlook.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Following this news, <em>DexCom</em> stock was trading down 39% during pre-market trading on July 26, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you purchased or otherwise acquired <em>DexCom</em> shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DEXCOM</em> ALERT: Bragar Eagel & Squire, P.C. is Investigating <em>DexCom</em>, <em>Inc</em>. on Behalf of <em>DexCom</em> Stockholders and Encourages Investors to Contact the Firm",
"sentiment": 0.7034,
"highlighted_in": "title"
}
]
},
{
"symbol": "DXCM.MX",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.99518,
"sentiment_score": 0.299233,
"highlights": [
{
"highlight": "., a nationally recognized stockholder rights law firm, is investigating potential claims against <em>DexCom</em>, <em>Inc</em>. (“<em>DexCom</em>” or the “Company”) (NASDAQ: DXCM) on behalf of <em>DexCom</em> stockholders. Our investigation concerns whether <em>DexCom</em> has violated the federal securities laws and/or engaged in other unlawful business practices.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On July 25, 2024, after the closure of market trading, <em>DexCom</em> issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>DexCom</em> revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to \"certain unique items impacting 2024 seasonality,\" which have been identified as factors influencing the Company’s financial outlook.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Following this news, <em>DexCom</em> stock was trading down 39% during pre-market trading on July 26, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you purchased or otherwise acquired <em>DexCom</em> shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DEXCOM</em> ALERT: Bragar Eagel & Squire, P.C. is Investigating <em>DexCom</em>, <em>Inc</em>. on Behalf of <em>DexCom</em> Stockholders and Encourages Investors to Contact the Firm",
"sentiment": 0.7034,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A4M.L",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 80.99131,
"sentiment_score": 0.299233,
"highlights": [
{
"highlight": "., a nationally recognized stockholder rights law firm, is investigating potential claims against <em>DexCom</em>, <em>Inc</em>. (“<em>DexCom</em>” or the “Company”) (NASDAQ: DXCM) on behalf of <em>DexCom</em> stockholders. Our investigation concerns whether <em>DexCom</em> has violated the federal securities laws and/or engaged in other unlawful business practices.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On July 25, 2024, after the closure of market trading, <em>DexCom</em> issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>DexCom</em> revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to \"certain unique items impacting 2024 seasonality,\" which have been identified as factors influencing the Company’s financial outlook.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Following this news, <em>DexCom</em> stock was trading down 39% during pre-market trading on July 26, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you purchased or otherwise acquired <em>DexCom</em> shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DEXCOM</em> ALERT: Bragar Eagel & Squire, P.C. is Investigating <em>DexCom</em>, <em>Inc</em>. on Behalf of <em>DexCom</em> Stockholders and Encourages Investors to Contact the Firm",
"sentiment": 0.7034,
"highlighted_in": "title"
}
]
},
{
"symbol": "D1EX34.SA",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.02235,
"sentiment_score": 0.299233,
"highlights": [
{
"highlight": "., a nationally recognized stockholder rights law firm, is investigating potential claims against <em>DexCom</em>, <em>Inc</em>. (“<em>DexCom</em>” or the “Company”) (NASDAQ: DXCM) on behalf of <em>DexCom</em> stockholders. Our investigation concerns whether <em>DexCom</em> has violated the federal securities laws and/or engaged in other unlawful business practices.",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "On July 25, 2024, after the closure of market trading, <em>DexCom</em> issued a press release announcing its financial results for the second quarter of 2024. The Company reported revenue figures amounting to $1.004 billion. However, the press release conveyed that the Company’s performance did not meet its established high standards of execution.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Furthermore, <em>DexCom</em> revised its revenue guidance for the full fiscal year of 2024, projecting a revenue range between $4 billion and $4.05 billion. This adjustment was attributed to \"certain unique items impacting 2024 seasonality,\" which have been identified as factors influencing the Company’s financial outlook.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Following this news, <em>DexCom</em> stock was trading down 39% during pre-market trading on July 26, 2024.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "If you purchased or otherwise acquired <em>DexCom</em> shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DEXCOM</em> ALERT: Bragar Eagel & Squire, P.C. is Investigating <em>DexCom</em>, <em>Inc</em>. on Behalf of <em>DexCom</em> Stockholders and Encourages Investors to Contact the Firm",
"sentiment": 0.7034,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "c9476cdb-d3d3-497b-b7b3-030c947eec3b",
"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and American Airlines and Encourages Investors to Contact the Firm",
"description": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...",
"keywords": "Bragar Eagel & Squire, CVS, Walgreens Boots Alliance, WBA, American Airlines, AAL, securities, class action, stockholder rights, legal, lawyer, litigate, lawsuit, a, Class Action",
"snippet": "NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actio...",
"url": "https://www.globenewswire.com/news-release/2024/07/27/2919923/0/en/Bragar-Eagel-Squire-P-C-Reminds-Investors-That-Class-Action-Lawsuits-Have-Been-Filed-Against-CVS-Walgreens-and-American-Airlines-and-Encourages-Investors-to-Contact-the-Firm.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/29481954-f2ff-4756-b5a9-d982a6497bd0",
"language": "en",
"published_at": "2024-07-27T01:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "WBA.BA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 36.26844,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS.SN",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.860802,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVSCL.SN",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 22.860739,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AAL",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 58.676796,
"sentiment_score": 0.12284,
"highlights": [
{
"highlight": "(NASDAQ: WBA), and <em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (<em>NASDAQ</em>: <em>AAL</em>). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Walgreens class action go to: https://bespc.com/cases/WBA\n\n<em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (<em>NASDAQ</em>: <em>AAL</em>)\n\nClass Period: January 25, 2024 - May 28, 2024\n\nLead Plaintiff Deadline: September 16, 2024\n\nOn May 28, 2024, after the market closed, <em>American</em> <em>Airlines</em> announced that its Chief Commercial Officer was departing.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>American</em> <em>Airlines</em>’ stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>American</em> <em>Airlines</em> class action go to: https://bespc.com/cases/AAL\n\nAbout Bragar Eagel & Squire, P.C.:\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and <em>American</em> <em>Airlines</em> and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "WBA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.023926,
"sentiment_score": -0.098667,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>WBA</em>), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>WBA</em>)\n\nClass Period: October 12, 2023 and June 26, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nThe complaint alleges that on June 27, 2024, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.",
"sentiment": -0.296,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "HCSG",
"name": "Healthcare Services Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 9.924631,
"sentiment_score": -0.5267,
"highlights": [
{
"highlight": "The Company stated that higher utilization of <em>healthcare</em> <em>services</em>, meaning more insurance dollars spent, weighed on its results in addition to Medicare reimbursement rate cuts that will continue to pressure CVS for the remainder of the year.",
"sentiment": -0.5267,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.62262,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE</em>: <em>CVS</em>), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (<em>NYSE</em>: <em>CVS</em>)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "A1G.DE",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Industrials",
"match_score": 42.953335,
"sentiment_score": 0.12284,
"highlights": [
{
"highlight": "(NASDAQ: WBA), and <em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Walgreens class action go to: https://bespc.com/cases/WBA\n\n<em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL)\n\nClass Period: January 25, 2024 - May 28, 2024\n\nLead Plaintiff Deadline: September 16, 2024\n\nOn May 28, 2024, after the market closed, <em>American</em> <em>Airlines</em> announced that its Chief Commercial Officer was departing.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>American</em> <em>Airlines</em>’ stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>American</em> <em>Airlines</em> class action go to: https://bespc.com/cases/AAL\n\nAbout Bragar Eagel & Squire, P.C.:\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and <em>American</em> <em>Airlines</em> and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "W8A.DE",
"name": "Walgreens Boots Alliance Inc",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.268074,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS.DE",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.860569,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AAL.MX",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Industrials",
"match_score": 42.953575,
"sentiment_score": 0.12284,
"highlights": [
{
"highlight": "(NASDAQ: WBA), and <em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Walgreens class action go to: https://bespc.com/cases/WBA\n\n<em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL)\n\nClass Period: January 25, 2024 - May 28, 2024\n\nLead Plaintiff Deadline: September 16, 2024\n\nOn May 28, 2024, after the market closed, <em>American</em> <em>Airlines</em> announced that its Chief Commercial Officer was departing.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>American</em> <em>Airlines</em>’ stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>American</em> <em>Airlines</em> class action go to: https://bespc.com/cases/AAL\n\nAbout Bragar Eagel & Squire, P.C.:\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and <em>American</em> <em>Airlines</em> and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "WBA.MX",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.268013,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVS.MX",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.86007,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0HE6.L",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 42.953804,
"sentiment_score": 0.12284,
"highlights": [
{
"highlight": "(NASDAQ: WBA), and <em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Walgreens class action go to: https://bespc.com/cases/WBA\n\n<em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL)\n\nClass Period: January 25, 2024 - May 28, 2024\n\nLead Plaintiff Deadline: September 16, 2024\n\nOn May 28, 2024, after the market closed, <em>American</em> <em>Airlines</em> announced that its Chief Commercial Officer was departing.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>American</em> <em>Airlines</em>’ stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>American</em> <em>Airlines</em> class action go to: https://bespc.com/cases/AAL\n\nAbout Bragar Eagel & Squire, P.C.:\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and <em>American</em> <em>Airlines</em> and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HRS.L",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 22.859858,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0LSZ.L",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 36.267746,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AALL34.SA",
"name": "American Airlines Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Industrials",
"match_score": 42.951447,
"sentiment_score": 0.12284,
"highlights": [
{
"highlight": "(NASDAQ: WBA), and <em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the Walgreens class action go to: https://bespc.com/cases/WBA\n\n<em>American</em> <em>Airlines</em> <em>Group</em> <em>Inc</em>. (NASDAQ: AAL)\n\nClass Period: January 25, 2024 - May 28, 2024\n\nLead Plaintiff Deadline: September 16, 2024\n\nOn May 28, 2024, after the market closed, <em>American</em> <em>Airlines</em> announced that its Chief Commercial Officer was departing.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "On this news, <em>American</em> <em>Airlines</em>’ stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the <em>American</em> <em>Airlines</em> class action go to: https://bespc.com/cases/AAL\n\nAbout Bragar Eagel & Squire, P.C.:\n\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, and <em>American</em> <em>Airlines</em> and Encourages Investors to Contact the Firm",
"sentiment": 0.3182,
"highlighted_in": "title"
}
]
},
{
"symbol": "WGBA34.SA",
"name": "Walgreens Boots Alliance, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 36.26462,
"sentiment_score": 0,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CVS Health Corporation (NYSE: CVS), <em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more information on the CVS class action go to: https://bespc.com/cases/CVS\n\n<em>Walgreens</em> <em>Boots</em> <em>Alliance</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CVSH34.SA",
"name": "CVS Health Corporation",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.860348,
"sentiment_score": 0.41355,
"highlights": [
{
"highlight": "., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of <em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS), Walgreens Boots Alliance, Inc. (NASDAQ: WBA), and American Airlines Group Inc. (NASDAQ: AAL).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CVS</em> <em>Health</em> <em>Corporation</em> (NYSE: CVS)\n\nClass Period: May 3, 2023 - April 30, 2024\n\nLead Plaintiff Deadline: September 10, 2024\n\nCVS is a healthcare company that operates through three primary segments: Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.",
"sentiment": 0.8271,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "08924a4b-75f0-4a77-b986-190e39426fb6",
"title": "Half Year 2024 Ucb SA Earnings Call Transcript",
"description": "Jul 25, 2024 / 12:00PM GMTAntje Witte - Ucb SA - Head of Investor Relations Good morning. Good afternoon. Good evening. Welcome to the UCB half-year 2024 Capita",
"keywords": "GuruFocus, Article, News, GuruFocus Research, OTCPK:UCBJF",
"snippet": "Jul 25, 2024 / 12:00PM GMT\n\nAntje Witte - Ucb SA - Head of Investor Relations\n\n\n\nGood morning. Good afternoon. Good evening. Welcome to the UCB half-year 2024 C...",
"url": "https://www.gurufocus.com/news/2483652/half-year-2024-ucb-sa-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-07-27T00:06:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "UCBJY",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.800026,
"sentiment_score": 0.4734,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nAntje Witte - <em>Ucb</em> <em>SA</em> - Head of Investor Relations\n\n\n\nGood morning. Good afternoon. Good evening. Welcome to the <em>UCB</em> half-year 2024 Capital Market call. My name is Antje. I'm the Head of Investor Relations at <em>UCB</em>.\n\n\n\nBefore I introduce you to the agenda and hand over to the speakers today, I'd like to make some remarks.",
"sentiment": 0.9468,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Ucb</em> <em>SA</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "UCBJF",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.71521,
"sentiment_score": 0.4734,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nAntje Witte - <em>Ucb</em> <em>SA</em> - Head of Investor Relations\n\n\n\nGood morning. Good afternoon. Good evening. Welcome to the <em>UCB</em> half-year 2024 Capital Market call. My name is Antje. I'm the Head of Investor Relations at <em>UCB</em>.\n\n\n\nBefore I introduce you to the agenda and hand over to the speakers today, I'd like to make some remarks.",
"sentiment": 0.9468,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Ucb</em> <em>SA</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "UCB.BR",
"name": "UCB SA",
"exchange": null,
"exchange_long": null,
"country": "be",
"type": "equity",
"industry": "Healthcare",
"match_score": 106.68248,
"sentiment_score": 0.4734,
"highlights": [
{
"highlight": "Jul 25, 2024 / 12:00PM GMT\n\nAntje Witte - <em>Ucb</em> <em>SA</em> - Head of Investor Relations\n\n\n\nGood morning. Good afternoon. Good evening. Welcome to the <em>UCB</em> half-year 2024 Capital Market call. My name is Antje. I'm the Head of Investor Relations at <em>UCB</em>.\n\n\n\nBefore I introduce you to the agenda and hand over to the speakers today, I'd like to make some remarks.",
"sentiment": 0.9468,
"highlighted_in": "main_text"
},
{
"highlight": "Half Year 2024 <em>Ucb</em> <em>SA</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 901,
"sentiment_avg": 0.2630853848941093
}
]
}
Other details
Entity count
- 11,338